“Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s21. doi:10.25251/skin.5.supp.21.